Servier announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) glioma following surgical intervention and for whom chemoradiotherapy can be delayed were published in The ...

InterVene, Inc., a privately held medical device company pioneering interventional devices for venous occlusions, announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Recana® Thrombectomy Catheter System for treating venous in-stent restenosis and native ...

Regeneron Pharmaceuticals, Inc. announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial, which evaluated Libtayo® (cemiplimab) plus platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or ...

Launching now in the U.S., INGELVAC CIRCOFLEX® AD is the first vaccine to combine both PCV2a and PCV2d antigens in a single dose designed for optimized herd health. Built on the industry-leading vaccine INGELVAC CIRCOFLEX® from Boehringer Ingelheim, which has set the global standard for PCV2 ...

Medtronic plc a global leader in healthcare technology, announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC), enabling integration ...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that it has submitted an IND (Investigational New Drug application) to the Ministry of Food and Drug Safety for a global Phase 3 clinical trial of SKYVaricella to ...